Graft versus Host Disease (GvHD) may occur following a bone marrow transplant or similar procedure when immune cells (white blood cells) in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”. GvHD is usually treated with steroids; however, when steroid medication fails – which happens in up to 50% of patients – the outcome is usually fatal. Approximately 30,000 allogeneic bone marrow transplants are undertaken each year and around 35%-50% of recipients will develop acute GvHD. So while acute GvHD is a rare condition it is nevertheless a major medical challenge and presents a sizeable global market.
Two-Phase 1 trials of products created through StemSmart™ technology have been completed on patients with GvHD, with successful outcomes; a success rate of 79% with adult patients and 90% with pediatric patients.